Electrical Storms in Brugada Syndrome: Review of Pharmacologic and Ablative Therapeutic Options

Maury P, MD*, Hocini M, MD†, Haïssaguerre M, MD‡

*University Hospital Rangueil, Toulouse, France.
†Hôpital Haut Lévèque, Pessac and University Victor Segalen Bordeaux II, France.

Address for correspondence: P. Maury, Federation of Cardiology, University Hospital Rangueil, 31059 Toulouse Cedex 09, France. Email: mauryjphil@hotmail.com

Abstract

Electrical storm occurring in a patient with the Brugada syndrome is an exceptional but malignant and potentially lethal event. Efficient therapeutic solutions should be known and urgently applied because of the inability of usual antiarrhythmic means in preventing multiple recurrences of ventricular arrhythmias. Isoproterenol should be immediately infused while oral quinidine should be further administrated when isoproterenol is not effective. In case of failure of these therapeutic options, ablation of the triggering ventricular ectopies should be attempted.

Key words: electrical storm; Brugada syndrome; isoproterenol; quinidine; ablation, ventricular fibrillation

The Brugada syndrome is an inherited cardiac electrical disorder occurring in the absence of obvious structural heart disease, initially defined by the association of right bundle branch block, ST elevation in right precordial leads and sudden cardiac death related to polymorphic ventricular tachycardias.

In Brugada syndrome, the prevalence of malignant ventricular arrhythmias varies from 5 % at two years follow-up in asymptomatic patients to 45 % in patients with previous cardiac arrest. While in most patients, a single arrhythmic event occurs, some patients will suffer electrical storms. Although there is no commonly accepted definition for this event, electrical storm is generally perceived as the rapid or incessant succession of recurrent poorly tolerated ventricular arrhythmias, generally requiring repeated cardioversions, occurring during a short period of time (Figure 1). Electrical storm is fortunately a very scarce phenomenon, but which can occur twice or more in the same patient, or can be the first manifestation of the disease.

True prevalence of electrical storm in Brugada syndrome has not been evaluated, such events having only been seldom reported in isolated case reports. To our knowledge, to date, only twelve such cases have been published.

Although exceptional, electrical storm in Brugada syndrome is a major event with dramatic consequences, leading sometimes to a fast ineluctable arrhythmic death in otherwise healthy patients.
young people despite all usual antiarrhythmic interventions. Heart transplantation has even been once performed for such an intractable electrical storm. That’s why some particular crucial and efficient therapeutic considerations should be known and urgently applied in order to avoid a fatal outcome.

**Figure 1:** Repeated onset of polymorphic arrhythmias on ECG monitoring, as could be observed during electrical storm occurring in patients with Brugada syndrome

**Pharmacological Management**

Causal factors should be searched and immediately corrected, such as fever, increased vagal tone during gastro-enteritis, low potassium blood levels, non febrile bronchitis or infusion of class 1 drugs for diagnostic purposes.

Apart from class 1A agents (see further) no antiarrhythmic drug has been shown to be effective in preventing recurrence of arrhythmia in Brugada syndrome, then antiarrhythmic drugs should be better avoided in case of electrical storm. Beta-blocker, bretylate, lidocaine, mexiletine or magnesium has been tried without any success or can even worsen the situation. In the DEBUT study, there was an 18 % death rate in Thai patients survivors of Sudden Unexpected Death Syndrome which were treated with beta-blocker. If amiodarone infusion has been once
apparently successful (but concomitantly with a beta-adrenergic agonist, see further) it did not seem to be beneficial in other cases. Sotalol, a drug devoid of class 1 effect, seems to have been successful in one case, however, one should remind that class 3 drugs also can increase ST elevation that may be deleterious.

Isoproterenol infusion at a sufficient dosing, ranging usually from 0.1 to 1-3 µg/mn, should be immediately started. Although isoproterenol is generally proarrhythmic in most other conditions, it is an effective drug in electrical storms related to Brugada syndrome and prevents recurrences of ventricular fibrillation (VF).

Both Brugada electrocardiographic pattern and ventricular excitability or vulnerability are believed to be dependent on the sympathetic imbalance and on cardiac rate. Worsening of the electrophysiological conditions have been described when vagal tonus increases and/or heart rate decreases. Major arrhythmic events and sudden death are known to frequently occur at night, when the vagal tone is predominant. In patients with Brugada syndrome, isoproterenol infusion normalizes the electrocardiographic pattern and avoids ventricular fibrillation induction during electrophysiological study.

Beta-adrenergic stimulation with isoproterenol increases and restores the dome of epicardial action potentials, reducing the degree of local and transmural heterogeneity. This can be sufficient to decrease the degree of ST elevation and to avoid the genesis of premature beats. Beta-adrenergic stimulation should be optimally performed using isoproterenol, since failure of dobutamine infusion had been reported, although cilostazol - e.g. an oral phosphodiesterase inhibitor - has also been shown to be efficient in preventing recurrent VF in Brugada syndrome.

Accelerating the heart rate (decreasing or decreasing the vagal tonus (decreasing and increasing I_{CaL}) for example by atropine infusion, can also act, particularly when associated to beta agonist. However atropine infusion alone has been sometimes tried without any beneficial result, while success or failure of fast pacing have been reported.

In some cases, VF is incessant despite major adrenergic stimulation due to the physical and emotional stress caused by the repeated shocks. The associated alpha-adrenergic stimulation, which is leading to ST elevation in Brugada syndrome, is suspected to overwhelm the beneficial effects of beta-adrenergic stimulation in those cases.

Class 1A drugs like quinidine are another means to escape from such a critical situation and should be tested in patients with electrical storm not immediately responding to isoproterenol. Oral quinidine has been successfully used in electrical storms in Brugada syndrome.

Quinidine is a class 1 agent and should theoretically worsen the situation because of its sodium channel blocking properties. However quinidine is also a blocker of the transient outward current I_{to}. Blocking I_{to} counteracts the marked abbreviation of action potentials in epicardial cells and so normalizes ECG pattern and ventricular vulnerability. Experimentally, class 1A drugs restore the action potential dome, normalize ST segment elevation and prevent arrhythmogenesis by blocking I_{to}. Anticholinergic properties of class 1A agents would also contribute to this beneficial effect.

In 1987, Belhassen and coll. first document the ability of class 1A agents for prevention of inducibility in patients with idiopathic VF, which is believed to be caused in a large part by Brugada syndrome. Long term beneficial action of quinidine has then been described in a...
population of idiopathic VF and Brugada syndrome. In this study, lack of inducible arrhythmia under class 1A drugs (mainly quinidine) was possible in 80% of patients with the Brugada syndrome and in all patients with idiopathic VF, and displayed good prognostic value since no recurrent arrhythmia could be documented after a mean follow-up of 9 years when patients were treated with class 1A agents (quinidine 1 to 2 g daily). In a recent publication of the same group, quinidine bisulfate at a mean dose of 1.5 g daily prevented inducibility in 88% of patients with Brugada syndrome, without any recurrence of arrhythmia with a mean follow-up of 56 months. Normalization of the ECG pattern and suppression of the ventricular premature beats as well as the induction of VF by quinidine (1 to 1.5 g daily) has also been described by other groups in isolated cases.

Hydroquinidine chlorydrate (600 to 900 mg daily) has also been recently shown to normalize the ECG pattern in 34% of patients with Brugada syndrome, to prevent arrhythmia inducibility in 76% of asymptomatic patients, to prevent the occurrence of arrhythmic events in 90% of those patients in which arrhythmia was rendered non inducible, and to avoid any recurrence of arrhythmia in implanted patients presenting with repeated shocks.

The effect of others class 1A drugs is more controversial. Disopyramide, another blocker of I_{to}, is believed to be potent but in a lesser extent: disopyramide can sometimes increase ST elevation and may be proarrhythmic or antiarrhythmic according to the associated conditions; in fact it has been shown to prevent inducibility while exaggerating the ECG pattern in one case and was inefficient in another case. Procainamide increases ST elevation and is proposed for the drug challenge for diagnosis of Brugada syndrome; it failed to prevent VF induction and to normalize the ECG pattern in one case of idiopathic VF with right bundle branch, considered as a variant form of Brugada syndrome. Other agents which block I_{to} without significant block of I_{Na}, such as tedisamil, a drug currently in clinical trials for atrial fibrillation, could also be useful in this situation.

The only side effect would be an excessive QT prolongation. Because of the blocking action of class 1A drugs on repolarizing K currents, these agents could unmask an associated LQT syndrome, since some congenital LQT syndrome and Brugada syndrome are both linked to mutations of the sodium channel and can coexist in the same patients. Indeed, excessive QT prolongation in this context has been reported, although not observed by others.

Finally, in case of incessant VF recurring despite all these therapeutic options, general anesthesia has been sometimes performed with good results, although failure has been reported.

Non Pharmacological Management

Interventional therapy has been recently developed for treating electrical storm, and appears promising in such critical situations. Even if ventricular premature beats are rather infrequent in patients with Brugada syndrome, ICD-stored electrograms and ECG monitoring have shown that ventricular premature beats (VPB’s) precede spontaneous VF in the majority of cases and that they are identical to the one initiating the arrhythmias, which are always induced by the same premature beat in a given patient.

Whether they induced VF or not, VPB’s in Brugada syndrome usually originate from the right ventricular outflow tract (RVOT), although right ventricular ectopics with left axis have been described. Isolated cases of monomorphic ventricular tachycardia have
been also reported, with left bundle block morphology with inferior\textsuperscript{42,43} or superior axis\textsuperscript{41,44,45} or even with right bundle block morphology\textsuperscript{8,14,16}, whose relationship with Brugada syndrome could be incidental or not, but which could also be incessant\textsuperscript{14} and lead to fatal electrical storm\textsuperscript{8}. Arrhythmogenic preponderance of the right ventricular outflow tract is not surprising due to the local higher electrical gradient, as otherwise illustrated by the ST elevation which is usually exclusively present in right precordial leads.

![Figure 2](image_url)

**Figure 2:** 12 lead-ECG with typical ST elevation in right precordial leads and monomorphic ventricular bigeminy during drug challenge (Ajmaline infusion). These characteristic ventricular ectopies can be usually documented in Brugada syndrome, with left bundle block morphology and inferior axis, arising in the right ventricular outflow tract. These ectopies can trigger multi-recurrent arrhythmias and have to be targeted by radiofrequency ablation when interventional procedure is needed.
Current observations suggest an important role for VPB’s of right ventricular origin in the Brugada syndrome. Chinushi et al.\textsuperscript{46} described recurrent episodes of VF in a patient with Brugada syndrome initiated by monomorphic VPB’s with left bundle block morphology. This was corroborated by Morita et al.\textsuperscript{47} who observed VPB’s in 9 out of 45 patients studied. Eleven VPB morphologies were observed in these 9 patients, of which 10 were of right ventricular origin (7 lateral RVOT, 2 septal RVOT and 1 from the apex).

While the cornerstone of the management of these conditions has been the implantation of a defibrillator, these reports and our recent success with the ablation of idiopathic VF\textsuperscript{48,49} has led us to evaluate the role of trigger elimination in patients with Brugada syndrome\textsuperscript{37,50}. We have studied four patients with Brugada syndrome (3 males, age 36 ± 8 years). These patients presented with documented episodes of polymorphic ventricular tachycardia or VF (1 to 21 episodes), 3 with a family history of sudden death. They had 12 ± 9 episodes of VF or syncpe prior to mapping. No drug therapy had been attempted in 3 patients with Brugada syndrome while quinidine failed in 1 patient. The Brugada syndrome was diagnosed by abnormal QRST complexes in leads V1 and V2 with a coved ST segment elevation in 4 patients, one who had a familial SCN5A channelopathy. No patient had evidence of structural heart disease based on physical examination, echocardiography and right/left ventricular ejection fraction. Exercise testing and coronary angiography excluded myocardial ischemia. Brugada syndrome had been diagnosed 9 months and 3 years prior to the clinical episodes of VF in 2 patients.

All patients were studied within 2 weeks of their arrhythmic storm and had been documented to have frequent VPB’s. The triggering role of VPB’s in the initiation of VF was observed by ambulatory monitoring or stored electrograms of the defibrillator. Premature beats in the Brugada syndrome were monomorphic in all, coming from the RVOT in three patients (left bundle branch-inferior axis morphology, coupling interval of 343 ± 59 ms) and with left bundle branch block-superior axis morphology in one (coupling interval 278 ± 29 ms). The monomorphic VPB’s were first observed at the time of VF in 2 patients, whereas in 2 patients they had been documented together with a normal ECG 14 and 11 years before they triggered VF, preceding the apparition of ECG abnormalities. Exercise testing and isoproterenol infusion eliminated all premature beats, excluding catecholaminergic polymorphic ventricular tachycardia.

Mapping and ablation was performed as previously described in patients with idiopathic VF\textsuperscript{49}. In the three patients with RVOT origin, VPB’s were eliminated by 7-10 minutes of radiofrequency energy applications at the earliest site of activity. In the fourth patient, the VPB’s were found to originate from the anterior right ventricular Purkinje network. Ten minutes of radiofrequency energy application eliminated all VPB’s in this patient. Noteworthy is that the inducibility of VF was modified after ablation. During a mean follow-up period of 9 ± 8 months there has been no recurrence of VF, syncope or sudden cardiac death in any patient.

While catheter ablation techniques are emerging, the initial experiences with idiopathic VF, and latterly with VF related to repolarization disorders have provided important insights into the role of focal triggers from RVOT and the Purkinje system in the initiation of VF associated with a number of clinical substrates in humans. Reducing the incidence of VF with localized ablation may reduce defibrillation requirement and replacement and improve the patients’ quality of life. The excellent long-term results after successful ablation of these triggers has been confirmed utilizing the data-logging capabilities of defibrillators in many of these patients and is being achieved in several centers.
References

1. Brugada P, Brugada J. Right bundle branch block, persistant ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 1992; 20: 1391-1396.

2. Brugada J, Brugada R, Brugada P. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14: 455-457.

3. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm. Sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102: 742-747.

4. Credner SC, Klingehenbeben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 33: 1909-1915.

5. Ayerza MR, De Zutter M, Goethals M, Wellens F, Geelen P, Brugada P. Heart transplantation as last resort against Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 943-944.

6. Maury P, Couderc P, Delay M, Boveda S, Brugada J. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 2004; 6: 130-3.

7. Chalvidan T, Deharo JC, Dieuzaide P, Defaye P, Djiane P. Near fatal electrical storm in a patient equipped with an implantable cardioverter-defibrillator for Brugada syndrome. Pacing Clin Electrophysiol 2000; 23: 410-412.

8. Dinckal MH, Davutoglu V, Akdemir I, Soydinc S, Kirilmaz A, Aksoy M. Incessant monomorphic ventricular tachycardia during febrile illness in a patient with Brugada syndrome: fatal electrical storm. Europace 2003; 5: 257-261.

9. Shimizu W, Kamakura S. Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol 2001; 34 Suppl: 173-175.

10. Suzuki H, Torigoe K, Numata O, Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11: 1277-1280.

11. Tanaka H, Kinoshita O, Uchikawa S, et al. Successful Prevention of Recurrent Ventricular Fibrillation by Intravenous Isoproterenol in a Patient with Brugada Syndrome. Pacing Clin Electrophysiol 2001; 24: 1293-1294.

12. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 2004; 27: 821-823.

13. Nakamura M, Isobe M, Imamura H. Incessant ventricular fibrillation attacks in a patient with Brugada syndrome. Int J Cardiol 1998; 64: 205-206.

14. Pinar Bermudes E, Garcia-Alberola A, Martinez Sanchez J, Sanchez Munoz JS, Valdes Chavarri M. Spontaneous sustained monomorphic ventricular tachycardia after administration of ajmaline in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000; 23: 407-409.
15. Gonzalez Rebollo JM, Hernandez Madrid A, Garcia A, Garcia de Castro A, Mejias A, Moro C. Recurrent ventricular fibrillation during a febrile illness in a patient with the Brugada syndrome. Rev Esp Cardiol 2000 ; 53 : 755-757.

16. Sastry BK, Narasimhan C, Soma Raju B. Brugada syndrome with monomorphic ventricular tachycardia in a one-year-old child. Indian Heart J 2001 ; 53 : 203-205.

17. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001 ; 24 : 1420-1422.

18. Wilde AAM, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RNW, Kass RS, Nademanee K, Priori SG, Towbin JA. Proposed diagnostic criteria for the Brugada syndrome. Circulation 2002 ; 106 : 2514-2519.

19. Morita H, Morita ST, Nagase S, Banha K, Nishii N, Tani Y, Watanabe A, Nakamura K, Kusano KF, Emori T, Matsubara H, Hina K, Kita T, Ohe T. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003 ; 42 : 1624-1631.

20. Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome : is an implantable cardioverter defibrillator the only therapeutic option ? Pacing Clin Electrophysiol 2002 ; 25 : 1634-1640.

21. Alings M, Wilde A. « Brugada » syndrome : clinical data and suggested pathophysiological mechanisms. Circulation 1999 ; 99 : 666-673.

22. Kasanuki H, Ohnishi S, Ohtura M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997 ; 95 : 2277-2285.

23. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for Unexpected death in Thailand (DEBUT) : a randomized clinical trial. Circulation 2003 ; 107 : 2221-2226.

24. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K and Towbin J. Diagnosis. In Camm AJ ed : Clinical approaches to tachyarrhythmias (vol 10 : The Brugada Syndrome). Futura Publishing Co., Inc., New York, 1999, p 43-50.

25. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K and Towbin J. Pathogenesis and role of the autonomic nervous system. In Camm AJ ed : Clinical approaches to tachyarrhythmias (vol 10 : The Brugada Syndrome). Futura Publishing Co., Inc., New York, 1999, p 33-38 and p 45-47.

26. Antzelevitch C. Ion and channels and ventricular arrhythmias : cellular and ionic mechanisms underlying the Brugada syndrome. Curr Opin Cardiol 1999 ; 14 : 274-279.

27. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome J Cardiovasc Electrophysiol 2002 ; 13 : 698-701.

28. Yan GX, Antzelevitch C. Cellular basis for the Brugada Syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999 ; 100 : 1660-1666.
29. Miyazaki T, Mitamura AH, Miyoshi S, Soejima K, Aizawa Y and Ogawa S. Autonomic and antiarrhythmic modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-1070.

30. Proclemer A, Facchin D, Feruglio GA, Nucifora R. Recurrent ventricular fibrillation, right bundle branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report. G Ital Cardiol 1993; 23: 1211-1218.

31. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731-1737.

32. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10: 1301-1312.

33. Garg A, Finneran W, Feld GK. Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. J Cardiovasc Electrophysiol 1998; 9: 642-647.

34. Hermida S, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheny P, Di Fusco S, Rey JL, Cauchemez B, Leenhardt A. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860.

35. Chinushi M, Aizawa Y, Ogawa Y, Shiba M, Takahashi K. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J Electrocardiol 1997; 30: 133-136.

36. Priori SG, Napolitano C, Schwartz PJ, Bloise R, crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome. The role of flecainide challenge. Circulation 2000; 102: 945-947.

37. Haïssaguerre M, Extramiana F, Hocini M, Cauchemez B, Jaïs P, Cabrera JA, Farre G, Leenhardt A, Sanders P, Scavée C, Hsu LF, Weerasooriya R, Shah DC, Frank R, Maury P, Delay M, Garrigue S, Clémenty J. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndrome. Circulation 2003, 108: 925-928.

38. Bansch D, Ouyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, Ernst S, Kuck KH. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108: 3011-3016.

39. Nakazawa K, Sakurai T, Takagi A, Kishi R, Osada K, nanke T, Miyake F, Matsumoto N, Kobayashi S. Autonomic imbalance as a property of symptomatic Brugada syndrome. Circ J 2003; 67: 511-514.

40. Kakishita M, Kurita T, Matsuo K, Taguchi A, Suyama K, Shimmizu W, Aihara N, Kamakura S, Yamamoto F, Kobayashi J, Kosakai Y, Ohe T. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000; 36: 1646-1653.
41. Boersma LVA, Jaarsma W, Jessurun ER, Van Hemel NHM, Wever EFD. Brugada syndrome: a case report of monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2001; 24: 112-115.

42. Shimada M, Miyazaki T, Miyoshi S, Soejima K, Hori S, Mitamura H, Ogawa S. Sustained monomorphic ventricular tachycardia on a patient with Brugada syndrome. Jpn Circ J 1996; 60: 364-370.

43. Vanpee D, Blommaert D, Gillet JB, De Roy L. A young man with recurrent syncopes, right bundle branch block and ST segment elevation. Am J Emerg Med 1999; 17: 601-603.

44. Martini B, Nava A, Ruzza L, Cannas S, Bauce B, Muriago A. La sindrome « morte improvvisa giovanile, blocco di branca destra e sopraslivellamento del stratto ST ». Giornale Italiano di Aritmologia e cardiostimulazione 1999; 2: 157-177.

45. Viskin S, Belhassen B. Clinical problem-solving: when you only live twice. New Engl J Med 1995; 332: 1221-1225.

46. Chinushi M, Washizuka T, Chinushi Y, Higuchi K, Toida T, Aizawa Y. Induction of ventricular fibrillation in Brugada syndrome by site-specific right ventricular premature depolarization. Pacing Clin Electrophysiol 2002; 25: 1649-1651.

47. Morita H, Fukushima-Kusano K, Nagase S, Takenaka-Morita S, Nishii N, Kakishita M, Nakamura K, Emori T, Matsubara H, Ohe T. Site-specific arrhythmogenesis in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2003; 14: 373-379.

48. Haissaguerre M, Shah DC, Jais P, Shoda M, Kautzner J, Arentz T, Kalushe D, Kadish A, Griffith M, Gaita F, Yamane T, Garrigue S, Hocini M, Clementy J. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet 2002; 359: 677-678.

49. Haissaguerre M, Shoda M, Jais P, Nogami A, Shah DC, Kautzner J, Arentz T, Kalushe D, Lamaison D, Griffith M, Cruz F, De Paola A, Gaita F, Hocini M, Garrigue S, Macle L, Weerasooriya R, Clementy J. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002; 106: 962-967.

50. Haissaguerre M, Weerasooriya R, Waleczak F, Val Meijas J, Szumowski L, Hocini M, et al. Catheter ablation of polymorphic ventricular tachycardia or ventricular fibrillation in multiple substrates. In Santini M ed : Non pharmacological treatment of sudden death. Arianna Editrice, Bologna, 2003, p 237-253.